Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC-016 in Advanced Gastric and Pancreatic Cancer
NCT05277987Phase 1Unknown
- Sponsor
- Luohu District People's Hospital
- Start
- Mar 2022
- Primary completion
- Mar 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HEC-016 in gastric adenocarcinoma, esophagogastric junction adenocarcinoma (GEJA) and pancreatic cancer (PC), sponsored by Luohu District People's Hospital. Primary endpoint: Dose Limiting Toxicity at 28 days. Status: unknown.
02
Drugs
HEC-016
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05277987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277987.